The study indicates that desmopressin prophylaxis prior to a native kidney biopsy in patients with a serum creatinine above 150 μmol/L reduces the risk for major and overall biopsy complications, especially in women.
less overall (3.4% vs 8.4%, OR 0.39, CI 0.17-0.90) whereas major or minor complications were not different. While desmopressin did not exhibit difference in complications in men, women received less major (0% vs 8.6%, P = 0.03) and overall complications (0% vs 12.1%, P = 0.006). A multiple logistic regression revealed that, after adjusting for BMI, age and sex, prophylaxis with desmopressin showed less major (OR 0.38, CI 0.15-0.96) and overall complications (OR 0.36, CI 0.15-0.85).
Conclusion:
Desmopressin given before a native kidney biopsy in patients with impaired renal function can reduce the risk for complications.
Kidney biopsies are essential for optimal diagnosis and treatment in many diseases. With the development of the uraemic state the risk for bleeding complications increases. On a theoretical basis, to avoid bleeding complications, some protocols include subcutaneous desmopressin (1-deamino-8D-arginine vasopressin [DDAVP] , Octostim®) as prophylaxis before the biopsy to improve haemostasis. 1 Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin and was found to decrease the bleeding time in patients with uraemia. 2, 3 The administration of desmopressin is controversial in the literature. Some researchers showed that the risk for bleeding complications is probably still higher for patients after treatment of prolonged bleeding time with desmopressin as compared to patients with a normal bleeding time before the biopsy. [4] [5] [6] [7] [8] Some studies favour the desmopressin treatment before kidney biopsies, 9 while others are more restrictive. 8 This study was performed to evaluate if the administration of desmopressin alters the risk for renal biopsy complications.
METHODS
In this study, 576 consecutive native kidney biopsies (407 male, 169 female) with a serum creatinine above 150 μmol/L in 527 patients (372 men and 155 women, median age 61 years) were included (Table 1) . Data were mainly collected prospectively (six medical centres) while mixed retrospective and prospective data were collected from one centre (total prospective 87% of native kidney biopsies). The data were collected from 1 January 2006 until 9 October 2015. The study was approved by the Regional Ethical Review Board. At one of the hospitals all patients with a serum creatinine above 150 μmol/L received desmopressin, subcutaneous (dose 0.3 μg/kg) before biopsies as prophylaxis. In 204 native kidney biopsies desmopressin was used before the biopsies; while in 372 native kidney biopsies not.
The biopsies were performed under ultrasound guidance (i.e. an ultrasound machine Logiq E9 with 2-5 MHz-sector transducer [GE Healthcare, Chalfont St Giles, UK] or similar) with an automated spring-loaded biopsy device. The biopsy procedure, used standard protocol and the processing of the biopsy specimens were described previously. 10, 11 16 Gauge (G) (Magnum and Max-Core by BARD Medical, Covington, GA, USA; HTR 16/15 by Tsunami Medical, San Possidonio, Italy) respective 18 G (Magnum by BARD Medical, Covington, GA, USA; BioPince by Angiotech, Vancouver, BC, Canada) biopsy needles were used. The bleeding time was measured before native kidney biopsies at two centres during the beginning of the study and later these centres stopped using this measurement.
Biopsies were performed by radiologists (87%) and nephrologists (13%). Native kidney biopsies were performed as inpatient-procedures. Kidney function was calculated using estimated glomerular filtration rate (eGFR MDRD). 12 Blood pressure was measured as systolic and diastolic and also given as mean arterial pressure (MAP, mmHg). Biopsy complications were divided into "major" (e.g. bleeding requiring blood transfusion, acute hydronephrosis, septicaemia, etc.) that require an intervention (e.g. a blood transfusion and/or invasive procedure), and "minor" that resolve spontaneously without intervention (e.g. gross haematuria). 4, 13 For the statistical analysis the IBM SPSS Statistic 22 (Armonk, NY, USA) were used. Fisher's exact test and χ 2 analyses were used for test of data and given as odds ratio (OR) and confidence interval (CI). Univariate and multiple binary logistic regression analyses using Enter method were used with complications as outcome. A two sided P-value of <0.05 was considered significant.
RESULTS
In native kidney biopsies with a serum creatinine >150 μmol/L, the rate for overall biopsy complications was 6.6% (major 5.2%, minor 1.4%). Patients treated with desmopressin (n = 204) versus those without desmopressin (n = 372) showed fewer overall complications (3.4% vs 8.4%, OR 0.39, CI 0.17-0.90, P = 0.027) whereas major and minor biopsy complications were not significantly different. When exploring men and women separately, there was a greater desmopressin effect among women than among men. Women with desmopressin as prophylaxis had less major (0% vs 8.6%, P = 0.03) and overall complications (0% vs 12.1%, P = 0.006); while in men desmopressin made no difference. For native kidney biopsies, when a multiple logistic regression with major respectively overall complications as outcome was performed and adjustment for BMI, age and sex were done as potential confounders (Tables 2 and 3) , prophylaxis with desmopressin resulted in a reduction of major complications (OR 0.38 with 95% CI (0.15-0.96), P = 0.041) ( Table 4) and overall complications (OR 0.36 with 95% CI (0.15-0.85), P = 0.020) ( Table 5 ). Since there were only eight cases of minor complications no multiple logistic regression of those was performed. No interaction between the variables in the model was found. No negative side effects of treatment with desmopressin have been registered. There was no difference in complications between biopsies performed in patients not receiving desmopressin prophylaxis with serum creatinine ≤150 compared to those with creatinine >150 μmol/L.
DISCUSSION
The present study showed that patients with a creatinine above 150 μmol/L and receiving desmopressin as prophylaxis before native kidney biopsies had fewer overall biopsy complications compared to patients without desmopressin prophylaxis. This significant effect was especially found for women who received desmopressin. Since native kidney biopsies in women more frequently results in complications 10,14 a plausible beneficial effect of desmopressin is helpful in clinical practice. A benefit of desmopressin also seems present for men since fewer complications were found after adjusting for sex, age and BMI. The only existing randomised controlled trial (RCT) of prebiopsy desmopressin prophylaxis versus placebo in native kidney biopsies showed that only the risk of "minor" biopsy complications (development of perinephric hematoma and hematoma size) was reduced when treated with desmopressin before the biopsy procedure. 9 However, in that RCT-study (80 vs 82 patients) desmopressin was used only in "low-risk"-patients who were defined as patients with eGFR ≥60 mL/min per Table 3 Univariate analysis of overall complications in native kidney biopsies with a serum creatinine >150 μmol/L. , serum creatinine ≤1,5 mg/dL [130 μmol/L], blood pressure < 140/90 mmHg, normal coagulation, no severe obesity and no acute kidney injury. This limited material also indicates benefit of desmopressin in "low-risk" patients. The present study supports the benefit of desmopressin also for patients with more impaired renal function. Another retrospective smaller study (66 patients with desmopressin) in native kidney biopsies could not verify a difference in bleeding complications with versus without desmopressin. 15 No negative side-effects of treatment with desmopressin were registered in this study. However, desmopressin is a potent drug that may cause side-effects with clinical relevance. In a case report hyponatraemia was found to be related to excess fluid intake and administration of desmopressin. The patient had suffered from headache, nausea, muscle cramps and tonic clonic seizure that recovered without sequelae. 16 There exist other reports of side effect to desmopressin such as arterial and venous thrombosis, tachycardia and flushing. 8 On the other side, hyponatraemia is seldom described after administration of a single dose desmopressin. 17 This motivates assessment of electrolytes such as sodium prior to biopsy to clarify if the patient is at risk and further a proper observation and monitoring of the patients for such side-effects. Studies about other drugs used as prophylaxis for bleeding complications in renal biopsies are ongoing and need further confirmation, for example, some authors had found that bleeding complications were reduced in renal biopsies when using Reptilase and vitamin K1 as prophylaxis. 1 The present study indicates that the cut off value of creatinine, by itself, is not a separate reason for complications, since no differences existed between the group with a creatinine ≤150 compared to those with >150 μmol/L if desmopressin was not administered.
More extended comparative studies with and without desmopressin as prophylaxis before renal biopsies may help to further clarify its effect. The primary aim of this study was to analyze an eventual effect of desmopressin. Negative sideeffects of desmopressin would have been reported in the protocol. However, metabolic variables such as development of hyponatraemia may have been missed, unless clinically evident, since such electrolyte derangements were not specifically examined in the study.
In conclusion, the present study indicates that desmopressin prophylaxis prior to a native kidney biopsy in patients with a serum creatinine above 150 μmol/L reduces the risk for major and overall biopsy complications, especially in women. 
